In a large, real-world survey of asthma1
  • A validated tool included questions about symptom frequency, need for rescue therapy, and functional abilities at work and home
  • 55% of asthma patients were uncontrolled
  • Uncontrolled patients were nearly 6 times more likely to be hospitalized multiple times per year
  • >50% of uncontrolled patients reported attacks that were seemingly life threatening






The burden of asthma

cornerstone

Other facts about asthma patients

  • Asthma patients lose >10 million workdays each year in the US2
  • Asthma patients may be limited in their abilities to perform normal daily activities3
  • Noncompliance with controller medications increased ER visits and hospitalizations4
Please see Important Safety Information and full Prescribing Information.




Important Safety Information


ZYFLO CR® is a leukotriene synthesis inhibitor indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Do not use ZYFLO CR® to treat an acute asthma attack.

ZYFLO CR® is contraindicated for patients with active liver disease or persistent hepatic function enzyme elevations  3 times the upper limit of normal. Assessment of hepatic function enzymes prior to and during ZYFLO CR® therapy should be undertaken. ZYFLO CR® is also contraindicated for patients with a history of allergic reactions to zileuton or any of the other ingredients.

The active ingredient in ZYFLO CR® increases theophylline, warfarin, and propranolol levels. Dose adjustment of these other drugs and patient monitoring may be required. ZYFLO CR® should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Neuropsychiatric events, including sleeping disorders and behavioral changes, may occur with ZYFLO CR®.

The most common adverse reactions (>5%) include: sinusitis, nausea, and pharyngolaryngeal pain.